Urothelial cancer (UC) is a common urologic disease that has the highest recurrence rate of any malignancy. The most common type is urothelial carcinoma which can affect different organs of the urinary tract. The field of UC is facing a phenomenal evolution with the development of novel therapies that are highly promising for this disease which still has a poor prognosis. Systemic therapies, intravesical therapies as well as innovation in surgical management are giving hope to clinicians to improve patient outcomes. Furthermore, novel therapeutic targets and treatment strategies hold promise to improve the outcome of patients afflicted with this malignancy. The wide range of diseases from NMIC to MIC through UTUC or urethral carcinoma require some challenging skills from the clinicians to adapt, improve and provide the better care according to the patient and tumors characteristics.
The aim of this Research Topic will be to provide an understanding of how systemic and local therapy has been integrated into the optimal perioperative management of UC. This includes the current knowledge available regarding systemic therapies, new targets, novel local therapy, and new therapeutic strategies and how they have been integrated into surgical management. To be able to cover and implement the field of perioperative management, we want this Research Topic to provide discussion around current practices and propose new perspectives for daily care and for the future of urothelial carcinoma care for clinicians. We would also like to emphasize optimal management for patients with localized urothelial carcinoma.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Urothelial cancer (UC) is a common urologic disease that has the highest recurrence rate of any malignancy. The most common type is urothelial carcinoma which can affect different organs of the urinary tract. The field of UC is facing a phenomenal evolution with the development of novel therapies that are highly promising for this disease which still has a poor prognosis. Systemic therapies, intravesical therapies as well as innovation in surgical management are giving hope to clinicians to improve patient outcomes. Furthermore, novel therapeutic targets and treatment strategies hold promise to improve the outcome of patients afflicted with this malignancy. The wide range of diseases from NMIC to MIC through UTUC or urethral carcinoma require some challenging skills from the clinicians to adapt, improve and provide the better care according to the patient and tumors characteristics.
The aim of this Research Topic will be to provide an understanding of how systemic and local therapy has been integrated into the optimal perioperative management of UC. This includes the current knowledge available regarding systemic therapies, new targets, novel local therapy, and new therapeutic strategies and how they have been integrated into surgical management. To be able to cover and implement the field of perioperative management, we want this Research Topic to provide discussion around current practices and propose new perspectives for daily care and for the future of urothelial carcinoma care for clinicians. We would also like to emphasize optimal management for patients with localized urothelial carcinoma.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
